Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus bevacizumab versus interferon alfa-2a plus bevacizumab in first-line metastatic clear cell renal cell carcinoma
NL-OMON34911Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Everolimus + bevacizumab with Interferon alfa-2a + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: active, not recruiting.
02
Drugs
everolimusbevacizumabinterferon alfa-2a
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON34911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34911.